Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
- 1 March 2003
- journal article
- website
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (3) , 445-449
- https://doi.org/10.1046/j.1538-7836.2003.00083.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII geneBritish Journal of Haematology, 2001
- Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyBlood, 2001
- Deep Venous Thrombosis and Thalidomide Therapy for Multiple MyelomaNew England Journal of Medicine, 2001
- Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse modelsBlood, 2001
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myelomaBritish Journal of Haematology, 1998
- Factor VIII and Factor-VIII-Related Antigen in Multiple Myelomatosis and Related ConditionsBritish Journal of Haematology, 1976
- High Antihaemophilic Factor in Multiple MyelomaNature, 1965